BMJ  2004;329:1343-1344 (4 December), doi:10.1136/bmj.329.7478.1343-d

Letter

TADS study raises concerns

EDITOR—We have additional concerns to those raised by Lenzer about the adolescents with depression study (TADS).^{1 2}

TADS consists of two separate randomised studies: a double blind comparison of fluoxetine (109 subjects) with placebo (112), and an unblinded comparison between cognitive behaviour therapy alone (111) and fluoxetine plus cognitive behaviour therapy (107). The lack of patient blinding and placebo control in the latter group is likely to exaggerate the benefit seen in the fluoxetine plus cognitive behaviour therapy group, who receive more face to face contact and know (as do their doctors) that they are not receiving placebo.

Comparing results across all four groups is therefore misleading. The authors' claim that a cognitive behaviour therapy plus placebo arm would have been both too expensive and too artificial to have clinical relevance is unconvincing.

TADS found no statistical advantage of fluoxetine over placebo on the primary end point, the children's depression rating scale (CDRS-R; P = 0.10), but this was not mentioned in the abstract. This and the small or absent advantages of fluoxetine on other end points (table) and in other studies,³ shows that fluoxetine, like all other antidepressants, is of doubtful clinical importance for children.

View this table: [in this window] [in a new window]   Effect of fluoxetine and placebo on various end points

 

Adverse events and suicidal behaviour may be greater than the TADS paper says. Despite small numbers, more subjects leaving the study than reporting adverse effects, and the splitting of adverse events into multiple groups, significantly more psychiatric adverse events occurred in the fluoxetine group than the placebo group (² test (1 df), P = 0.047). Despite small numbers and the exclusion of known suicidal behaviour, TADS found a trend to more suicidal behaviour (six attempts in the fluoxetine groups and one attempt in the non-fluoxetine groups), consistent with other trials of selective serotonin reuptake inhibitors (SSRIs). We are less reassured than the authors by the fact that no attempt was fatal. Suicide is a rare event so that a study the size of TADS should be expected to miss a significantly increased risk.

The data do not support the TADS authors' optimistic conclusions. The balance between benefit and harm of SSRI treatment for depression in childhood and adolescence has yet to be shown to be favourable.

Department of Psychological Medicine, Women's and Children's Hospital, North Adelaide 5006, Australia jureidinij{at}wch.sa.gov.au

University of Adelaide, Adelaide 5005, Australia

---

Additional authors are Peter Parry, child psychiatrist, Women's and Children's Hospital, North Adelaide; David B Menkes, professor of psychological medicine, University of Wales Academic Unit, Wrexham; and Chris Doecke, associate professor of pharmacy practice, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide.

Competing interests: None declared.

References

1. Lenzer J. Journalists on Prozac. BMJ 2004;329: 748. (25 September.)[Free Full Text]
2. Treatment for Adolescents with Depression Study Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292: 807-20.[Abstract/Free Full Text]
3. Jureidini J, Doecke C, Mansfield P, Haby M, Menkes D, Tonkin A. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328: 879-83.[Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Authors of TADS study reply to letter raising concerns

John S March for the TADS Group
BMJ 2005 330: 730-731. [Extract] [Full Text]

Rethinking childhood depression: Does childhood depression exist?

D B Double
BMJ 2005 330: 418. [Extract] [Full Text] [PDF]

Journalists on Prozac

Jeanne Lenzer
BMJ 2004 329: 748. [Extract] [Full Text]

Efficacy and safety of antidepressants for children and adolescents

Jon N Jureidini, Christopher J Doecke, Peter R Mansfield, Michelle M Haby, David B Menkes, and Anne L Tonkin
BMJ 2004 328: 879-883. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• The TADS Team, (2007). The Treatment for Adolescents With Depression Study (TADS): Long-term Effectiveness and Safety Outcomes. Arch Gen Psychiatry 64: 1132-1143 [Abstract] [Full text]  
• TONKIN, A., JUREIDINI, J. (2005). Wishful thinking: antidepressant drugs in childhood depression. Br. J. Psychiatry 187: 304-305 [Full text]  
• March, J. S, for the TADS Group, (2005). Authors of TADS study reply to letter raising concerns. BMJ 330: 730-731 [Full text]  
• Double, D B (2005). Rethinking childhood depression: Does childhood depression exist?. BMJ 330: 418-418 [Full text]  

Rapid Responses:

Read all Rapid Responses

TADS critiques lack scientific rigor, accuracy and thus credibility

John S. March, et al.
bmj.com, 24 Dec 2004 [Full text]